DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Sanyal A, Charles ED, Neuschwander-Tetri BA. et al.
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Lancet 2019;
392 (10165): 2705-2717
We do not assume any responsibility for the contents of the web pages of other providers.